187 related articles for article (PubMed ID: 19369244)
21. [Management of uveal melanomas, guidelines for oncologists].
Mathis T; Cassoux N; Tardy M; Piperno S; Gastaud L; Dendale R; Maschi C; Nguyen AM; Meyer L; Bonnin N; Baillif S; Tick S; Mouriaux F; Jaspart F; Dellis J; Rosier L; Desjardins L; Herault J; Caujolle JP; Thariat J
Bull Cancer; 2018 Oct; 105(10):967-980. PubMed ID: 30217336
[TBL] [Abstract][Full Text] [Related]
22. Immunomagnetic bead separation of mononuclear cells from contaminating granulocytes in cryopreserved blood samples.
Preobrazhensky SN; Bahler DW
Cryobiology; 2009 Dec; 59(3):366-8. PubMed ID: 19766618
[TBL] [Abstract][Full Text] [Related]
23. Infiltrative T regulatory cells in enucleated uveal melanomas.
Lagouros E; Salomao D; Thorland E; Hodge DO; Vile R; Pulido JS
Trans Am Ophthalmol Soc; 2009 Dec; 107():223-8. PubMed ID: 20126498
[TBL] [Abstract][Full Text] [Related]
24. Analysis of inflammatory cells in uveal melanoma after prior irradiation.
Vu TH; Bronkhorst IH; Versluis M; Marinkovic M; van Duinen SG; Vrolijk J; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):360-9. PubMed ID: 23211827
[TBL] [Abstract][Full Text] [Related]
25. Comparison of primary and secondary enucleation for uveal melanoma.
Pham CM; Custer PL; Couch SM
Orbit; 2017 Dec; 36(6):422-427. PubMed ID: 28812919
[TBL] [Abstract][Full Text] [Related]
26. Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: analysis of 7872 consecutive eyes.
Shields CL; Kaliki S; Livesey M; Walker B; Garoon R; Bucci M; Feinstein E; Pesch A; Gonzalez C; Lally SE; Mashayekhi A; Shields JA
JAMA Ophthalmol; 2013 Aug; 131(8):993-1003. PubMed ID: 23681424
[TBL] [Abstract][Full Text] [Related]
27. Uveal melanoma in young patients.
Pogrzebielski A; Orłowska-Heitzman J; Romanowska-Dixon B
Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1646-9. PubMed ID: 16636835
[TBL] [Abstract][Full Text] [Related]
28. Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma.
Triozzi PL; Elson P; Aldrich W; Achberger S; Tubbs R; Biscotti CV; Singh AD
Melanoma Res; 2013 Feb; 23(1):1-7. PubMed ID: 23196330
[TBL] [Abstract][Full Text] [Related]
29. Metastasis from uveal melanoma associated with congenital ocular melanocytosis: a matched study.
Mashayekhi A; Kaliki S; Walker B; Park C; Sinha N; Kremer FZ; Shields CL; Shields JA
Ophthalmology; 2013 Jul; 120(7):1465-8. PubMed ID: 23522968
[TBL] [Abstract][Full Text] [Related]
30. Serum adiponectin, insulin resistance, and uveal melanoma: clinicopathological correlations.
Sevim DG; Kiratli H
Melanoma Res; 2016 Apr; 26(2):164-72. PubMed ID: 26630661
[TBL] [Abstract][Full Text] [Related]
31. [Ocular retention in patients with uveal melanoma managed by a multimodality approach].
García-Alvarez C; Muiños Y; Saornil MA; Almaraz A; López-Lara F; Frutos JM; Muñoz MF
Arch Soc Esp Oftalmol; 2009 Mar; 84(3):145-9. PubMed ID: 19340720
[TBL] [Abstract][Full Text] [Related]
32. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100.
Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R
J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866
[TBL] [Abstract][Full Text] [Related]
33. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma.
Scholes AG; Hagan S; Hiscott P; Damato BE; Grierson I
Arch Ophthalmol; 2001 Mar; 119(3):373-7. PubMed ID: 11231770
[TBL] [Abstract][Full Text] [Related]
35. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
36. Multicentric recurrent uveal melanoma.
Menon V; Thulasidas M; Narula R; Mulay K; Honavar SG
Indian J Ophthalmol; 2020 Oct; 68(10):2305-2307. PubMed ID: 32971703
[TBL] [Abstract][Full Text] [Related]
37. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients.
Marini O; Spina C; Mimiola E; Cassaro A; Malerba G; Todeschini G; Perbellini O; Scupoli M; Carli G; Facchinelli D; Cassatella M; Scapini P; Tecchio C
Oncotarget; 2016 May; 7(19):27676-88. PubMed ID: 27050283
[TBL] [Abstract][Full Text] [Related]
38. Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma.
Barisione G; Fabbi M; Gino A; Queirolo P; Orgiano L; Spano L; Picasso V; Pfeffer U; Mosci C; Jager MJ; Ferrini S; Gangemi R
JAMA Ophthalmol; 2015 Sep; 133(9):1013-21. PubMed ID: 26068448
[TBL] [Abstract][Full Text] [Related]
39. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1219-27. PubMed ID: 17325166
[TBL] [Abstract][Full Text] [Related]
40. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients.
Schmielau J; Finn OJ
Cancer Res; 2001 Jun; 61(12):4756-60. PubMed ID: 11406548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
